Abstract 2452
Background
Circulating tumor DNA (ctDNA) has been known to be released from tumor cells and evaluated as potential biomarkers for therapeutic responses. In our previous study, we proved applicability for KRAS mutation as a prognostic marker in pancreatic ductal adenocarcinoma (PDA) through the quantitative analysis of ctDNA using KRAS multiplex kit which covers 7 sites. In this study, we analyzed distribution of each single mutation in tumor and ctDNA by performed droplet digital PCR (ddPCR).
Methods
Total of 126 PDA patients were enrolled and analyzed for tumor DNA. We found 94 patients have samples for matched ctDNA analysis. Plasma was separated by established method and ctDNA were extracted using QIAamp Circulating Nucleic Acid Kit. QX200 Droplet Digital PCR System was applied to measure frequency of KRAS mutations using KRAS screening multiplex kit and probe for G12D, G12V and G12C in ctDNA and tumor DNA. Then, we compared the frequency between multiplex and single point mutation of KRAS.
Results
The positivity of mutation of tumor and ctDNA in multiplex ddPCR were 96.0% (n = 121/126) and 60.3% (n = 76/126), respectively. Positive rates of G12D, G12V and G12C were 59.6%, 24.5% and 22.3% in tumor and 36.2%, 16.0% and 17.0% in ctDNA, respectively. There was a correlation between multiplex and the sum of single point mutation (r = 0.805). In the single point mutation results, 44 of the samples detected in both tumor and ctDNA mutations were detected in the same site (75.9%), 12 of them were partially identical (19.0%), and 3 were inconsistent (5.2%). Comparing the frequency with other studies, G12D and G12V showed no difference in frequency, but G12C showed a higher positive rate than the previous studies even though we did not analysis for G12R. Multiple KRAS mutations were found in 17% and 6.4% in tumor and ctDNA.
Conclusions
These results show that the frequency of KRAS mutation correlated with tumor tissue and ctDNA. Also multiple mutations were detected high proportion compared to the previous studies. Further studies are needed to determine G12R proportion. We further evaluate whether the single point mutation detected by single probe is more valuable than sum of mutations from KRAS multiplex kit as a biomarker for predicting the prognosis of PDA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun-Young Kong.
Funding
National Cancer Center and the Ministry of Health & Welfare, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract